On March 19, 2014, Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) received a letter from the Listing Qualifications department of The NASDAQ Stock Market LLC notifying the Company that it no longer complies with the requirement to maintain a minimum of $10 million in stockholders’ equity for continued listing on the Nasdaq Global Select Market as set forth in Nasdaq Listing Rule 5450(b)(1)(A). Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) shares after opening at $1.01 moved to $1.05 on last trade day and at the end of the day closed at $0.929. Company price to sales ratio in past twelve months was calculated as 1.19 and price to cash ratio as 6.30. Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) showed a negative weekly performance of -5.19%.
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) holds the promise of developing an all-oral HCV regimen that can be competitive in the evolving HCV treatment landscape. It is the only small-cap biotech company with HCV drug candidates in three key classes NS5A, nucleotide NS5B polymerase and protease inhibitors. Early pre- and clinical data for these candidates demonstrated strong potency and favourable drug profiles. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares fell -6.19% in last trading session and ended the day on $2.73. ACHN return on equity ratio is recorded as -34.20% and its return on assets is -32.00%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) yearly performance is -60.94%.
Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) Net loss for 2013 was $130.7 million, or basic and diluted net loss per share available to common stockholders of $1.32, compared with net loss for 2012 of $91.8 million, or basic and diluted net loss per share available to common stockholders of $1.28. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) shares moved down -7.45% in last trading session and was closed at $4.47, while trading in range of $4.38 – $4.78. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) year to date (YTD) performance is -16.14%.
Synthetic Biologics, Inc. (NYSEMKT:SYN) a biotechnology company, announced positive preclinical research findings for SYN-005, the company’s proprietary monoclonal antibody (mAb) combination therapy for treating Pertussis (whooping cough), in two non-human primate studies (n=15). Synthetic Biologics Inc. (NYSEMKT:SYN) weekly performance is 12.70%. On last trading day company shares ended up $2.84. Synthetic Biologics Inc. (NYSEMKT:SYN) distance from 50-day simple moving average (SMA50) is 4.22%. Analysts mean target price for the company is $3.94.